Department of Obstetrics & Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, China.
The Women & Children Hospital Affiliated to Jiaxing University, 2468 Middle Ring Eastern Road, Jiaxing City, Zhejiang, 314000, China.
Nanomedicine (Lond). 2024;19(18-20):1615-1627. doi: 10.1080/17435889.2024.2368449. Epub 2024 Jul 17.
To evaluate a liposome complex conjugated with anti-epidermal growth factor receptor (EGFR) antibodies for the treatment of pre-eclampsia (PE). In experiments, the transfection rate, silencing effect and cytotoxicity were determined. In the PE model, the siRNA distribution, mean arterial pressure, 24-h urine protein concentration, serum sFlt1 concentration, number of viable fetuses and placental weight were measured. The nanomedicine effectively reduced the expression of sFIt1 and had a strong ability to target placental tissues. It could significantly reduce the symptoms of pre-eclampsia and improve pregnancy outcomes in PE model rats. The constructed nanomedicine can improve pregnancy outcomes in a rat model of pre-eclampsia and provides a new strategy for the treatment of pre-eclampsia.
为了评估一种与抗表皮生长因子受体（EGFR）抗体偶联的脂质体复合物在子痫前期（PE）治疗中的应用。在实验中，测定了转染率、沉默效果和细胞毒性。在 PE 模型中，测量了 siRNA 分布、平均动脉压、24 小时尿蛋白浓度、血清 sFlt1 浓度、活胎数和胎盘重量。该纳米药物有效降低了 sFIt1 的表达，具有靶向胎盘组织的强大能力。它可显著减轻 PE 模型大鼠的子痫前期症状并改善妊娠结局。所构建的纳米药物可以改善子痫前期大鼠的妊娠结局，为子痫前期的治疗提供了新策略。
